Vadasz Brian, Arazi Mattan, Shukha Yousef, Koren Ofir, Taher Riad
The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Internal Medicine Department E, Rambam HealthCare Campus, Ein IbrahimUmm alfahm, POD 4147, 300100, Haifa, Israel.
J Med Case Rep. 2021 Feb 14;15(1):62. doi: 10.1186/s13256-020-02607-2.
Euglycemic diabetic ketoacidosis is an uncommon but life-threatening complication associated with the use of sodium-glucose cotransporter 2 inhibitors that causes lower than expected blood glucose levels typically seen in diabetic ketoacidosis.
We present a case of 64-year-old Caucasian male patient previously diagnosed with type 2 diabetes treated with a sodium-glucose cotransporter 2 inhibitor who developed severe ketoacidosis. Serum glucose levels on initial presentation were slightly above normal baseline level. The patient was revealed to have latent autoimmune diabetes in adults.
This case highlights the importance of prescribing sodium-glucose cotransporter 2 inhibitors to the correct patient population and the significance of accurately differentiating between various types of diabetes.
正常血糖性糖尿病酮症酸中毒是一种与使用钠-葡萄糖协同转运蛋白2抑制剂相关的罕见但危及生命的并发症，它会导致糖尿病酮症酸中毒中通常所见的血糖水平低于预期。
我们报告一例64岁的白种男性患者，此前被诊断为2型糖尿病，接受钠-葡萄糖协同转运蛋白2抑制剂治疗，该患者发生了严重酮症酸中毒。初次就诊时的血清葡萄糖水平略高于正常基线水平。该患者被发现患有成人隐匿性自身免疫性糖尿病。
本病例强调了为正确的患者群体开具钠-葡萄糖协同转运蛋白2抑制剂的重要性，以及准确区分各种类型糖尿病的意义。
